KALA KALA BIO, Inc. Insider Trading

BAKER BROS. ADVISORS LP sold 730,408 shares (730.4K) at blended avg $1.45, exiting 63.2% of position as KALA stock has collapsed 92.2% from 52-week high.

BAKER BROS. ADVISORS LP executed 4 separate sales totaling 730,408 shares for $1,056,722.08 on 2025-09-30 and 2025-10-01, reducing holdings from 1,155,414 shares to 425,006 shares (63.2% reduction). The sales occurred at $1.60 and $1.38, notably near the bottom of a severe drawdown: the stock is currently trading at $77.00, which is 92.2% below its 52-week high of $981.50 and has fallen 87.4% over the past 30 days. The timing coincides with the company operating in a deeply unprofitable state (net income $-11,155,000.00 on revenue of $420,000.00 in the latest quarter) and a severely depressed market cap of $540,620,080.00. This large exit by a substantial holder during extreme distress, combined with the company's operational losses and revenue collapse, merits close examination of whether this reflects deteriorating conditions or forced deleveraging.

Baker Bros. Advisors LP purchases 310,559 shares ($2.0M) at $6.44 as 10% owner; holds 1.08M post-transaction amid negative fundamentals.

Baker Bros. Advisors LP, a substantial 10% stakeholder in KALA Bio, executed 2 separate purchases totaling 310,559 shares for $1,999,999.96 on 2024-12-30, raising holdings by 40.2% to 1.08M shares. This material accumulation at $6.44/share occurred while the stock trades at $347.00, reflecting a market valuation that has fallen 22.9% from its 52-week high. The company's fundamentals are deeply troubled: quarterly revenue of $420,000.00 against a net loss of $-8,950,000.00, with annual revenue declining 100.0% and the firm unprofitable on a full-year basis. Baker Bros.' cross-ticker track record shows 16 prior open-market buys with a 0.00% 90-day win rate and an average 90-day return of -23.4%, establishing a pattern of poorly-timed market purchases.